By Kuldip K. Ambastha
Longeveron Inc. (LGVN), a biotechnology company focused on clinical stage therapies, had its stock price rise by +105.4% per share on Thursday, March 31, 2022. On this trading day, a great piece of news led to a great return. Lomecel-B has shown positive results from its Phase 1 trial testing on individuals with mild Alzheimer’s disease. The Phase 1 trial has shown that Lomecel-B was well-tolerated, may slow down cognitive decline, and could improve the quality of life of individuals. While Alzheimer’s disease has sadly taken so much from so many in the past and present, Lomecel-B and other such offerings could give us all hope for the future.
Keywords – Longeveron Inc., Longeveron, LGVN, biotechnology, biotech, clinical stage therapy, Lomecel-B, Phase 1 trial, Alzheimer’s disease, past, present, sadness, future, hope.
Disclosure – The principals and clients of Ambastha Financial LLC have no positions in LGVN.
Disclaimer – No recommendations are being made via this post. Past performance is not an indicator of future performance. As an investor, you should do your own research and seek professional advice from a Registered Investment Adviser (RIA). You can lose money by investing in stocks and other instruments. Ambastha Financial LLC does not assume any responsibility (legal or otherwise) for any losses that may occur as a result of actions taken based on this post. All content copyrighted © 2022 – Ambastha Financial LLC.
CONTACT US